Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice

Neuroscience

Volumn 97, Issue 3, 2000, Pages 419-424

  Chapman, S ^a   Sabo, T ^a   Roses, A D ^b   Michaelson, D M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Brain; Cholinergic; Dopaminergic; Transgenic mice

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CHOLINERGIC NERVE CELL; HISTOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; MOUSE; NONHUMAN; NORADRENERGIC NERVE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHOLINERGIC FIBERS; DOPAMINE; HUMANS; MALE; MICE; MICE, KNOCKOUT; NOREPINEPHRINE; PRESYNAPTIC TERMINALS;

EID: 0034035852     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00087-7     Document Type: Article

References (31)

1. Aubert I., Cecyre D., Gauthier S., Quirion R. Comparative ontogenic profile of cholinergic markers, including nicotinic and muscarinic receptors, in the rat brain. J. comp. Neurol. 369:1996;31-55.
2. Buttini M., Orth M., Bellosta S., Akeefe H., Pitas R.E., Wyss-Coray T., Mucke L., Mahley R.W. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19:1999;4867-4880.
3. Chapman J., Estupinan J., Asherov A., Goldfarb L.G. A simple and efficient method for apolipoprotein E genotype determination. Neurology. 46:1996;1484-1485.
4. Chapman S., Michaelson D.M. Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice. J. Neurochem. 70:1998;708-714.
5. Chen Y., Lomnitski L., Michaelson D.M., Shohami E. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience. 80:1997;1255-1262.
6. Cooper J.A., Howell B.W. Lipoprotein receptors: signaling functions in the brain? Cell. 97:1999;671-674.
7. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines I.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
8. Fisher A., Brandeis R., Chapman S., Pittel Z., Michaelson D.M. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J. Neurochem. 70:1998;1991-1997.
9. Francis P. T., Cross A. J. and Bowen D. M. (1994) Neurotransmitters and neuropeptides. In Alzheimer's Disease (eds Terry R. D. and Katzman R. and Bick K. L. Raven Press, New York.
10. Gordon I., Grauer E., Genis I., Sehayek E., Michaelson D.M. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 199:1995;1-4.
11. 3H]imipramine localization and relationship to serotonin transporter. J. Pharmac. exp. Ther. 252:1990;410-418.
12. Ignatius M.J., Gebicke-Harter P.J., Skene J.H., Schilling J.W., Weisgraber K.H., Mahley R.W., Shooter E.M. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natn. Acad. Sci. U.S.A. 83:1986;1125-1129.
13. Inzelberg R., Chapman J., Treves T.A., Asherov A., Kiperwasser S., Hilkewicz O., Virshovski R., Klimowitzki S., Korczyn A.D. Apolipoprotein E4 in Parkinson disease and dementia: new data and meta-analysis of published studies. Alzheimers Dis. Assoc. Disord. 12:1998;45-48.
14. Karnovsky M.J., Roots L.A. A direct cloning thiocholine method for cholinesterases. J. Histochem. Cytochem. 121:1964;219-222.
15. Knouff C., Hinsdale M.E., Mezdour H., Altenburg M.K., Watanabe M., Quarfordt S.H., Sullivan P.M., Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. clin. Invest. 103:1999;1579-1586.
16. Masliah E., Samuel W., Veinbergs I., Mallory M., Mante M., Saitoh T. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 751:1997;307-314.
17. Mennicken F., Savasta M., Peretti-Renucci R., Feuerstein C. Autoradiographic localization of dopamine uptake sites in the rat brain with 3H-GBR 12935. J. neural Transm. Gen. Sect. 87:1992;1-14.
18. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science. 264:1994;850-852.
19. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstyft J.G., Rubin E.M., Breslow J.L. Sever hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created. Cell. 71:1992;343-353.
20. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17:1994;525-530.
21. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., Mahley R.W., Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natn. Acad. Sci. U.S.A. 95:1998;10,914-10,919.
22. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. A. Rev. Med. 47:1996;378-400.
23. Saunders A.M., Strittmatter W.J., Schmechel D., St.George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crappermachlachlan D.R., Alberts M.J., Hullete C., Crain B., Goldgaber D., Roses A.D. Association of apolipoprotein E allele E4 with late onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
24. Sheng H., Laskowitz D.T., Bennett E., Schmechel D.E., Bart R.D., Saunders A.M., Pearlstein R.D., Roses A.D., Warner D.S. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J. Cereb. Blood Flow Metab. 18:1998;361-366.
25. Slotnick B.M., Leonard C.M. A Stereotaxic Atlas of the Albino Mouse Forebrain. 1975;Department of Health, Education and Welfare, Washington, DC.
26. Soininen H., Kosunen O., Helisalmi S., Mannermaa A., Paljarvi L., Talasniemi S., Ryynanen M., Riekkinen P.S. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci. Lett. 187:1995;79-82.
27. Sullivan P.M., Mezdour H., Quarfordt S.H., Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. clin. Invest. 102:1998;130-135.
28. 3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmac. exp. Ther. 260:1992;427-436.
29. Veinbergs I., Mallory M., Mante M., Rockenstein E., Gilbert J.R., Masliah E. Differential neurotrophic effects of apolipoprotein E in aged transgenic mice. Neurosci. Lett. 265:1999;218-222.
30. Wenham P.R., Price W.H., Blandell G. Apolipoprotein E genotyping by one-stage PCR [Letter]. Lancet. 337:1991;1158-1159.
31. Xu P.T., Schmechel D.E., Rothrock-Cristian T., Burkhart D.S., Qiu H.L., Popko B., Sullivan P., Maeda N., Saunders A.M. Human apolipoprotein E2, E3 and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol. Dis. 1:1996;229-245.